Relapsing Multiple Sclerosis

• FDA approval · 2024-06-05
  FDA Approved: TASCENSO ODT — Supplemental Application (Cycle Pharmaceuticals Ltd)

  FDA approved a supplemental application for Tasenso ODT (fingolimod lauryl sulfate), introducing a new orodispersible tablet formulation of …

• FDA approval · 2023-08-10
  FDA Approved: PONVORY — Supplemental Application (Janssen Pharmaceuticals, Inc)

  The FDA approved a supplemental application for PONVORY (ponesimod) from Janssen Pharmaceuticals, Inc.

• FDA approval · 2020-08-20
  FDA Approved: KESIMPTA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  The FDA approved a supplemental application for Kesimpta (ofatumumab) from Novartis Pharmaceuticals Corporation, expanding its label/indicat…

• FDA approval · 2019-07-19
  FDA Approved: COPAXONE — Supplemental Application (Teva Neuroscience, Inc.)

  FDA approved a supplemental application for COPAXONE (glatiramer acetate) by Teva Neuroscience, Inc.

• FDA approval · 2014-04-30
  FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)

  FDA approved a supplemental application for GILENYA (fingolimod HCl) from Novartis Pharmaceuticals Corporation.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.